Lilly’s donanemab granted FDA Breakthrough Therapy designation for AD
Eli Lilly and Company (Lilly) has received the US Food and Drug Administration (FDA) Breakthrough Therapy designation for its donanemab to treat Alzheimer’s disease. Donanemab is an investigational